Home > > > > > Report Detail

Premature Ejaculation - Market Insight, Epidemiology and Market Forecast - 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 100
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Premature Ejaculation - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Premature Ejaculation epidemiology and market outlook for the 7MM.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Premature Ejaculation Understanding and Treatment Algorithm

The market report provides the overview of the Premature Ejaculation by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Premature Ejaculation Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Premature Ejaculation in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Premature Ejaculation Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Premature Ejaculation Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Premature Ejaculation market.

Premature Ejaculation Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Premature Ejaculation Report Insights

- Patient Population in Premature Ejaculation

- Therapeutic Approaches in Premature Ejaculation

- Premature Ejaculation Pipeline Analysis

- Premature Ejaculation Market Size and Trends

- Premature Ejaculation Market Opportunities

- Impact of upcoming Therapies in Premature Ejaculation

Premature Ejaculation Report Key Strengths

- 10 Year Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Drugs Uptake

- Highly Analyzed Market

- Key Cross Competition

Premature Ejaculation Report Assessment

- Current Treatment Practices in Premature Ejaculation

- Unmet Needs in Premature Ejaculation

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

- The report will help to develop Business Strategies by understanding the trends shaping and driving the Premature Ejaculation market

- Organize sales and marketing efforts by identifying the best opportunities for Premature Ejaculation market

- To understand the future market competition in the Premature Ejaculation market.

Premature Ejaculation - Market Insight, Epidemiology and Market Forecast - 2028

Table of Contents

1. Report Introduction
2. Premature Ejaculation Market Overview at a Glance
2.1. Market Share Distribution of Premature Ejaculation in 2016
2.2. Market Share Distribution of Premature Ejaculation in 2028
3. Disease Background and Overview: Premature Ejaculation
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Premature Ejaculation in 7MM
4.3. Total Prevalent Patient Population of Premature Ejaculation in 7MM - By Countries
5. Epidemiology of Premature Ejaculation by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Premature Ejaculation
5.1.3. Sub-Type Specific cases of the Premature Ejaculation *
5.1.4. Sex- Specific Cases of the Premature Ejaculation *
5.1.5. Diagnosed Cases of the Premature Ejaculation
5.1.6. Treatable Cases of the Premature Ejaculation
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Premature Ejaculation
5.4.3. Sub-Type Specific cases of the Premature Ejaculation *
5.4.4. Sex- Specific Cases of the Premature Ejaculation *
5.4.5. Diagnosed Cases of the Premature Ejaculation
5.4.6. Treatable Cases of the Premature Ejaculation
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Premature Ejaculation
5.5.3. Sub-Type Specific cases of the Premature Ejaculation *
5.5.4. Sex- Specific Cases of the Premature Ejaculation *
5.5.5. Diagnosed Cases of the Premature Ejaculation
5.5.6. Treatable Cases of the Premature Ejaculation
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Premature Ejaculation
5.6.3. Sub-Type Specific cases of the Premature Ejaculation *
5.6.4. Sex- Specific Cases of the Premature Ejaculation *
5.6.5. Diagnosed Cases of the Premature Ejaculation
5.6.6. Treatable Cases of the Premature Ejaculation
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Premature Ejaculation
5.7.3. Sub-Type Specific cases of the Premature Ejaculation *
5.7.4. Sex- Specific Cases of the Premature Ejaculation *
5.7.5. Diagnosed Cases of the Premature Ejaculation
5.7.6. Treatable Cases of the Premature Ejaculation
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Premature Ejaculation
5.8.3. Sub-Type Specific cases of the Premature Ejaculation *
5.8.4. Sex- Specific Cases of the Premature Ejaculation *
5.8.5. Diagnosed Cases of the Premature Ejaculation
5.8.6. Treatable Cases of the Premature Ejaculation
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Premature Ejaculation
5.9.3. Sub-Type Specific cases of the Premature Ejaculation *
5.9.4. Sex- Specific Cases of the Premature Ejaculation *
5.9.5. Diagnosed Cases of the Premature Ejaculation
5.9.6. Treatable Cases of the Premature Ejaculation
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Premature Ejaculation
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Premature Ejaculation
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Premature Ejaculation : 7MM Market Analysis
12.1. 7MM Market Size of Premature Ejaculation
12.2. 7MM Percentage Share of drugs marketed for Premature Ejaculation
12.3. 7MM Market Sales of Premature Ejaculation by Products
13. Premature Ejaculation : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Premature Ejaculation in United States
13.1.2. Percentage Share of drugs marketed for Premature Ejaculation in United States
13.1.3. Market Sales of Premature Ejaculation by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Premature Ejaculation in Germany
13.2.1.2. Percentage Share of drugs marketed for Premature Ejaculation in Germany
13.2.1.3. Market Sales of Premature Ejaculation by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Premature Ejaculation in France
13.2.2.2. Percentage Share of drugs marketed for Premature Ejaculation in France
13.2.2.3. Market Sales of Premature Ejaculation by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Premature Ejaculation in Italy
13.2.3.2. Percentage Share of drugs marketed for Premature Ejaculation in Italy
13.2.3.3. Market Sales of Premature Ejaculation by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Premature Ejaculation in Spain
13.2.4.2. Percentage Share of drugs marketed for Premature Ejaculation in Spain
13.2.4.3. Market Sales of Premature Ejaculation by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Premature Ejaculation in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Premature Ejaculation in United Kingdom
13.2.5.3. Market Sales of Premature Ejaculation by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Premature Ejaculation in Japan
13.3.2. Percentage Share of drugs marketed for Premature Ejaculation in Japan
13.3.3. Market Sales of Premature Ejaculation by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Premature Ejaculation in 7MM
Table 2: Total Prevalent/Incident Cases of the Premature Ejaculation in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Premature Ejaculation in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Premature Ejaculation in United States (2016-2028)
Table 5: Sex- Specific Cases of the Premature Ejaculation in United States (2016-2028)
Table 6: Diagnosed Cases of the Premature Ejaculation in United States (2016-2028)
Table 7: Treatable Cases of the Premature Ejaculation in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Premature Ejaculation in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Premature Ejaculation in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Premature Ejaculation in Germany (2016-2028)
Table 11: Diagnosed Cases of the Premature Ejaculation in Germany (2016-2028)
Table 12: Treatable Cases of the Premature Ejaculation in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Premature Ejaculation in France (2016-2028)
Table 14: Sub-Type Specific cases of the Premature Ejaculation in France (2016-2028)
Table 15: Sex- Specific Cases of the Premature Ejaculation in France (2016-2028)
Table 16: Diagnosed Cases of the Premature Ejaculation in France (2016-2028)
Table 17: Treatable Cases of the Premature Ejaculation in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Premature Ejaculation in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Premature Ejaculation in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Premature Ejaculation in Italy (2016-2028)
Table 21: Diagnosed Cases of the Premature Ejaculation in Italy (2016-2028)
Table 22: Treatable Cases of the Premature Ejaculation in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Premature Ejaculation in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Premature Ejaculation in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Premature Ejaculation in Spain (2016-2028)
Table 26: Diagnosed Cases of the Premature Ejaculation in Spain (2016-2028)
Table 27: Treatable Cases of the Premature Ejaculation in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Premature Ejaculation in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Premature Ejaculation in UK (2016-2028)
Table 30: Sex- Specific Cases of the Premature Ejaculation in UK (2016-2028)
Table 31: Diagnosed Cases of the Premature Ejaculation in UK (2016-2028)
Table 32: Treatable Cases of the Premature Ejaculation in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Premature Ejaculation in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Premature Ejaculation in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Premature Ejaculation in Japan (2016-2028)
Table 36: Diagnosed Cases of the Premature Ejaculation in Japan (2016-2028)
Table 37: Treatable Cases of the Premature Ejaculation in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Premature Ejaculation in USD MM (2016-2028)
Table 42:7MM- Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Premature Ejaculation in USD MM (2016-2028)
Table 45: United States-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Premature Ejaculation in USD MM (2016-2028)
Table 48: Germany-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Premature Ejaculation in USD MM (2016-2028)
Table 51: France-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Premature Ejaculation in USD MM (2016-2028)
Table 54: Italy-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Premature Ejaculation in USD MM (2016-2028)
Table 57: Spain-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Premature Ejaculation in USD MM (2016-2028)
Table 60:UK-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Premature Ejaculation in USD MM (2016-2028)
Table 63: Japan-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Premature Ejaculation in 7MM
Figure 2: Total Prevalent/Incident Cases of the Premature Ejaculation in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Premature Ejaculation in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Premature Ejaculation in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Premature Ejaculation in United States (2016-2028)
Figure 6: Diagnosed Cases of the Premature Ejaculation in United States (2016-2028)
Figure 7: Treatable Cases of the Premature Ejaculation in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Premature Ejaculation in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Premature Ejaculation in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Premature Ejaculation in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Premature Ejaculation in Germany (2016-2028)
Figure 12: Treatable Cases of the Premature Ejaculation in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Premature Ejaculation in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Premature Ejaculation in France (2016-2028)
Figure 15: Sex- Specific Cases of the Premature Ejaculation in France (2016-2028)
Figure 16: Diagnosed Cases of the Premature Ejaculation in France (2016-2028)
Figure 17: Treatable Cases of the Premature Ejaculation in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Premature Ejaculation in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Premature Ejaculation in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Premature Ejaculation in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Premature Ejaculation in Italy (2016-2028)
Figure 22: Treatable Cases of the Premature Ejaculation in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Premature Ejaculation in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Premature Ejaculation in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Premature Ejaculation in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Premature Ejaculation in Spain (2016-2028)
Figure 27: Treatable Cases of the Premature Ejaculation in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Premature Ejaculation in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Premature Ejaculation in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Premature Ejaculation in UK (2016-2028)
Figure 31: Diagnosed Cases of the Premature Ejaculation in UK (2016-2028)
Figure 32: Treatable Cases of the Premature Ejaculation in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Premature Ejaculation in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Premature Ejaculation in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Premature Ejaculation in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Premature Ejaculation in Japan (2016-2028)
Figure 37: Treatable Cases of the Premature Ejaculation in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Premature Ejaculation in USD MM (2016-2028)
Figure 42:7MM- Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Premature Ejaculation in USD MM (2016-2028)
Figure 45: United States-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Premature Ejaculation in USD MM (2016-2028)
Figure 48: Germany-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Premature Ejaculation in USD MM (2016-2028)
Figure 51: France-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Premature Ejaculation in USD MM (2016-2028)
Figure 54: Italy-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Premature Ejaculation in USD MM (2016-2028)
Figure 57: Spain-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Premature Ejaculation in USD MM (2016-2028)
Figure 60:UK-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Premature Ejaculation in USD MM (2016-2028)
Figure 63: Japan-Market Share Premature Ejaculation by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Premature Ejaculation by Therapies in USD MM (2016-2028)

  • Global Overactive Bladder Treatment Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Overactive Bladder Treatment market size was valued at US$ 4989.1 million in 2023. With growing demand in downstream market, the Overactive Bladder Treatment is forecast to a readjusted size of US$ 6182.8 million by 2030 with a CAGR of 3.1% during review period. The research report highlights the growth potential of the global Overactive Bladder Treatment market. Overactive Bladder Treatment are expected to show stable growth......
  • Global Genitourinary Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 02-Jan-2024        Price: US 3380 Onwards        Pages: 110
    Market Overview of Global Genitourinary Drugs market: According to our latest research, the global Genitourinary Drugs market looks promising in the next 5 years. As of 2022, the global Genitourinary Drugs market was estimated at USD 30442.38 million, and it's anticipated to reach USD 32574.96 million in 2028, with a CAGR of 1.13% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global ......
  • Global Urinary Tract Infection Treatment Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 100
    Market Overview of Global Urinary Tract Infection Treatment market: According to our latest research, the global Urinary Tract Infection Treatment market looks promising in the next 5 years. As of 2022, the global Urinary Tract Infection Treatment market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. A urinary tract infection is an infection that can occur in any area of the urinary tract, i......
  • Global Overactive Bladder Treatment Market Research Report 2023, Forecast to 2028
    Published: 02-Nov-2023        Price: US 2680 Onwards        Pages: 130
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
  • Global Overactive Bladder Treatment Professional Survey Report 2023, Forecast to 2028
    Published: 02-Nov-2023        Price: US 3280 Onwards        Pages: 103
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
  • Global Overactive Bladder Treatment Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 17-Oct-2023        Price: US 3380 Onwards        Pages: 105
    Market Overview of Global Overactive Bladder Treatment market: According to our latest research, the global Overactive Bladder Treatment market looks promising in the next 5 years. As of 2022, the global Overactive Bladder Treatment market was estimated at USD 3983.87 million, and it's anticipated to reach USD 5304.63 million in 2028, with a CAGR of 4.89% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensiv......
  • Genitourinary Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 150
    Genitourinary Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genitourinary deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of genitourinary deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Underst......
  • Global Genitourinary Drugs Market Insights, Forecast to 2029
    Published: 14-Aug-2023        Price: US 4900 Onwards        Pages: 70
    The global Genitourinary Drugs market is projected to grow from US$ 29570 million in 2023 to US$ 35930 million by 2029, at a Compound Annual Growth Rate (CAGR) of 3.3% during the forecast period. The US & Canada market for Genitourinary Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029. The China market for Genitourinary Drugs is estimated to increase from $ million in 202......
  • Global Overactive Bladder Therapeutics Market Insights, Forecast to 2029
    Published: 28-Jun-2023        Price: US 4900 Onwards        Pages: 88
    Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device. Market Analysis and Insights: Global Overactive Bladder Therapeutics Market The global Overactive Bladder Therapeutics market is projected to grow from US$ 5240.8 million in 2023 t......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs